NORDSON CORP (NDSN Q1 FY2025 earnings call

• Sales were $615 million, at the low end of guidance due to soft demand in key end markets and foreign exchange headwinds, but order entry rates accelerated. - Atrion acquisition had solid performance. - Achieved 56% gross margin, 26% operating profit margin, 31% EBITDA margin, and converted free cash flow at nearly 150% of net income. - Balance sheet: Cash on hand $130 million, net debt $2.1 billion, leverage ratio 2.4x. Repurchased ~$60 million in shares, paid $45 million in dividends. - Product innovations: Nordson's SpinSAM Acoustic Inspection system won awards, QuadraPro manual X-ray System received an award, Orion Pro recognized for innovation. - Integration of Atrion: Visited new manufacturing sites, positive market acceptance of Atrion's Myocardial Protection System.

Industrial Precision Solutions: Sales were $300 million, a decrease of 11% compared to the prior year first quarter, down 8% organically and 3% due to unfavorable currency impacts. EBITDA was $113 million in the quarter or 38% of sales, a decrease of 10% compared to the prior year. Medical and Fluid Solutions: Sales increased 21% compared to the prior year's first quarter, driven by the acquired Atrion business. EBITDA for Medical and Fluid Solutions was $64 million or 33% of sales, an 8% increase from prior year EBITDA but with EBITDA margins down 400 basis points. Advanced Technology Solutions: Sales were $121 million, an 11% decrease compared to the prior year first quarter. First quarter EBITDA was $23 million for the segment or 19% of sales, in line with the prior year first quarter.

• Second quarter sales expected in the range of $650 million to $690 million and adjusted earnings in the range of $2.30 to $2.50 per diluted share. - Full year sales expected to be at the lower end of prior expectations due to slow start and geopolitical macro environment dynamics.

• Geopolitical and macroeconomic uncertainties. - Fluctuations in end market demand. - Currency translation impacts affecting sales performance.

Q: Help me understand electronics-related business performance and semi/electronics go-forward view?

A: Miss in ATS was timing of orders, but order entry progressed positively, expecting strong shipments through the year.

Q: When will interventional medical business see year-on-year growth aligned to long-term trajectory?

A: Tough comps through first half, inflection starting in Q3 and Q4.

Q: In ATS segment, what's the rationale for moving Measurement & Control Solutions out of IPS to ATS?

A: Overlap in customers with IPS, but product and technology more aligned with ATS; MCS was a positive contributor but not a big needle mover.

Q: Are there plans to achieve midpoint of EPS with slower top line start?

A: Confident in delivering earnings commitments even with sales at lower end by managing operations and cost structure.

Q: How much margin dilution was from Atrion and what's the outlook?

A: Majority of margin dilution from Atrion's lower margin, core MFS business had strong decremental performance, Atrion expected to improve margins to high-20s to low-30s.

Q: On IPS weaker growth, cause and outlook?

A: Comparables from strong prior backlogs, but orders strengthening and backlog growth seen, with modest sequential improvement in ARAG and other businesses.